Is it safe and feasible to transition from intravenous prostacyclins to selexipag in stable pulmonary arterial hypertension patients?
Transitioning from intravenous prostacyclins to selexipag using a standardized outpatient protocol appears feasible in carefully selected, stable patients with pulmonary arterial hypertension.
There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
Aldweib et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: